AR068109A1 - TETRACICLIC DERIVATIVES OF INDOL AND A PHARMACEUTICAL COMPOSITION - Google Patents
TETRACICLIC DERIVATIVES OF INDOL AND A PHARMACEUTICAL COMPOSITIONInfo
- Publication number
- AR068109A1 AR068109A1 ARP080103718A ARP080103718A AR068109A1 AR 068109 A1 AR068109 A1 AR 068109A1 AR P080103718 A ARP080103718 A AR P080103718A AR P080103718 A ARP080103718 A AR P080103718A AR 068109 A1 AR068109 A1 AR 068109A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocycloalkyl
- cycloalkyl
- heteroaryl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a derivados tetracíclicos de indol y a composiciones que comprenden por lo menos un derivado tetracíclico de indol. Estos compuestos son utiles en el tratamiento o en la prevencion de una infeccion viral o un trastorno relacionado con virus en un paciente. Reivindicacion 1: Un compuesto que tiene la formula (1) o una de sus sales, solvatos, ésteres o prodrogas aceptable para uso farmacéutico en donde X es -O-, -S-, -NH-, -N(R9)-, -OC(R8)2O- o -OC(R8)2N(R9)-; Y es =O, =NH, =NR9, =NSOR11, =NSO2R11 o =NSO2N(R11)2; Z es -N- o -C(R31)-; R1 es un enlace, -[C(R12)2]r-, -[C(R12)2]r-O-[C(R12)2]q-, -[C(R12)2]r-N(R9)-[C(R12)2]q-, -[C(R12)2]q-CH=CH-[C(R12)2]q-, -[C(R12)2]q-C:::C-[C(R12)2]q- o -[C(R12)2]q-SO2-[C(R12)2]q-; R4, R5, R6 y R7 son cada uno, de manera independiente, H, alquilo, alqueniIo, alquinilo, arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo, -[C(R12)2]q-haloalquilo, -[C(R12)2]q-hidroxialquilo, halo, hidroxi, -OR9, -CN, -[C(R12)2]q-C(O)R8, -[C(R12)2]q-C(O)OR9, -[C(R12)2]q-C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -[C(R12)2]q-NHC(O)R8, -[C(R12)2]q-NR8C(O)N(R9)2, -[C(R12)2]q-NHSO2R11, -[C(R12)2]q-S(O)pR11, -[C(R12)2]q-SO2N(R9)2 y -SO2N(R9)C(O)N(R9)2; o R4 y R5, junto con los átomos de carbono a los cuales están ligados, se unen para formar un grupo cíclico de 3 a 7 miembros, seleccionado entre cicloalquilo, heterocicloalquilo, arilo o heteroarilo, o R5 y R6, junto con los átomos de carbono a los cuales están ligados, se unen para formar un grupo cíclico de 3 a 7 miembros, seleccionado entre cicloalquilo, heterocicloalquilo, arilo o heteroarilo, o R6 y R7, junto con los átomos de carbono a los cuales están ligados, se unen para formar un grupo cíclico de 3 a 7 miembros, seleccionado entre cicloalquilo, heterocicloalquilo, arilo o heteroarilo, cada aparicion de R8 es de manera independiente H, alquilo, alquenilo, alquinilo, -[C(R12)2]q-arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo, haloalquilo, o hidroxialquilo, cada aparicion de R9 es de manera independiente H, alquilo, alquenilo, alquinilo, -[C(R12)2]q-arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo, haloalquilo o hidroxialquilo; R10 es H, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo, heteroarilo, en donde un grupo cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo o heteroarilo puede estar sustituido de manera opcional e independiente con hasta 4 sustituyentes, que están seleccionados cada uno de manera independiente de H, alquilo, alquenilo, alquinilo, arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo,-[C(R12)2]q-haloalquiIo, -[C(R12)2]q-hidroxialquilo, halo, hidroxi, -OR9, -CN, -[C(R12)2]q-C(O)R8, -[C(R12)2]q-C(O)OR9, -[C(R12)2]q-C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -[C(R12)2]q-NHC(O)R8, -[C(R12)2]q-NR8C(O)N(R9)2, -[C(R12)2]q-NHSO2R11, -[C(R12)2]q-S(O)pR11, -[C(R12)2]q-SO2N(R9)2 y -SO2N(R9)C(O)N(R9)2; de modo tal que cuando R1 es un enlace, R10 es distinto de H; cada aparicion de R11 es en manera independiente alquilo, arilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, heteroarilo, haloalquilo, hidroxi, o hidroxialquilo, en donde un grupo cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo o heteroarilo puede estar sustituido de manera opcional e independiente con hasta 4 sustituyentes, que están seleccionados cada uno de manera independiente entre -H, alquilo, alqueniIo, alquinilo, arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo, -[C(R12)2]q-haloalquilo, -[C(R12)2]q-hidroxialquilo, halo, hidroxi, -OR9, -CN, -[C(R12)2]q-C(O)R8, -[C(R12)2]q-C(O)OR9, -[C(R12)2]q-C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -[C(R12)2]q-NHC(O)R8, -[C(R12)2]q-NR8C(O)N(R9)2, -[C(R12)2]q-NHSO2alquilo, -[C(R12)2]q-NHSO2cicloalquilo, -[C(R12)2]q-NHSO2arilo, -[C(R12)2]q-SO2N(R9)2 y -SO2N(R9)C(O)N(R9)2; cada aparicion de R12 es de manera independiente H, halo, -N(R9)2, -OR9, alquilo, cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, en donde un grupo cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo puede estar sustituido de manera opcional e independiente con hasta 4 sustituyentes, que están seleccionados cada uno de manera independiente entre alquilo, halo, haloalquilo, hidroxialquilo, hidroxi, -CN, -C(O)alquilo, -C(O)Oalquilo, -C(O)NH-alquilo, -C(O)N(alquilo)2, -O-alquilo, -NH2, -NH(alquilo), -N(alquilo)2, -NHC(O)alquilo, -NHSO2alquilo, -SO2alquilo o -SO2NH-alquilo, o dos grupos geminales R12, junto con el átomo de carbono en comun al cual están ligados, se unen para formar un grupo cicloalquilo de 3 a 7 miembros, heterocicloalquilo de 3 a 7 miembros o C=O; cada aparicion de R30 es de manera independiente H, alquilo, alquenilo, alquinilo, arilo, -[C(R12)2]q-C(O)R8, -[C(R12)2]q-C(O)OR9, -[C(R12)2]q-C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -[C(R12)2]q-NHC(O)R8, -[C(R12)2]q-NR8C(O)N(R9)2, -[C(R12)2]q-NHSO2R11, -[C(R12)2]q-S(O)pR11, -[C(R12)2]q-SO2N(R9)2 y -SO2N(R9)C(O)N(R9)2, o cualquier R30 y R31, junto con los átomos de carbono a los cuales están ligados, se unen para formar un grupo cíclico de 3 a 7 miembros, seleccionado entre cicloalquilo, heterocicloalquilo, arilo y heteroarilo; R31 es H, alquilo, alquenilo, alquinilo, arilo; -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo, -[C(R12)2]q-haloalquilo, -[C(R12)2]q-hidroxialquilo, halo, hidroxi, -OR9, -CN, cada aparicion de p es de manera independiente 0, 1 o 2; cada aparicion de q es de manera independiente un numero entero que varía de 0 a 4; y cada aparicion de r es de manera independiente un numero entero que varía de 1 a 4.This refers to indole tetracyclic derivatives and compositions comprising at least one indole tetracyclic derivative. These compounds are useful in the treatment or prevention of a viral infection or a virus-related disorder in a patient. Claim 1: A compound having the formula (1) or one of its salts, solvates, esters or prodrugs acceptable for pharmaceutical use wherein X is -O-, -S-, -NH-, -N (R9) -, -OC (R8) 2O- or -OC (R8) 2N (R9) -; Y is = O, = NH, = NR9, = NSOR11, = NSO2R11 or = NSO2N (R11) 2; Z is -N- or -C (R31) -; R1 is a link, - [C (R12) 2] r-, - [C (R12) 2] rO- [C (R12) 2] q-, - [C (R12) 2] rN (R9) - [ C (R12) 2] q-, - [C (R12) 2] q-CH = CH- [C (R12) 2] q-, - [C (R12) 2] qC ::: C- [C ( R12) 2] q- or - [C (R12) 2] q-SO2- [C (R12) 2] q-; R4, R5, R6 and R7 are each, independently, H, alkyl, alkeny, alkynyl, aryl, - [C (R12) 2] q-cycloalkyl, - [C (R12) 2] q-cycloalkenyl, - [C (R12) 2] q-heterocycloalkyl, - [C (R12) 2] q-heterocycloalkenyl, - [C (R12) 2] q-heteroaryl, - [C (R12) 2] q-haloalkyl, - [C (R12) 2] q-hydroxyalkyl, halo, hydroxy, -OR9, -CN, - [C (R12) 2] qC (O) R8, - [C (R12) 2] qC (O) OR9, - [C (R12) 2] qC (O) N (R9) 2, - [C (R12) 2] q-OR9, - [C (R12) 2] qN (R9) 2, - [C (R12) 2] q -NHC (O) R8, - [C (R12) 2] q-NR8C (O) N (R9) 2, - [C (R12) 2] q-NHSO2R11, - [C (R12) 2] qS (O ) pR11, - [C (R12) 2] q-SO2N (R9) 2 and -SO2N (R9) C (O) N (R9) 2; or R4 and R5, together with the carbon atoms to which they are attached, bind to form a 3- to 7-membered cyclic group, selected from cycloalkyl, heterocycloalkyl, aryl or heteroaryl, or R5 and R6, together with the atoms of carbon to which they are attached, join to form a 3- to 7-membered cyclic group, selected from cycloalkyl, heterocycloalkyl, aryl or heteroaryl, or R6 and R7, together with the carbon atoms to which they are linked, bind to forming a 3 to 7 membered cyclic group, selected from cycloalkyl, heterocycloalkyl, aryl or heteroaryl, each occurrence of R8 is independently H, alkyl, alkenyl, alkynyl, - [C (R12) 2] q-aryl, - [ C (R12) 2] q-cycloalkyl, - [C (R12) 2] q-cycloalkenyl, - [C (R12) 2] q-heterocycloalkyl, - [C (R12) 2] q-heterocycloalkenyl, - [C ( R12) 2] q-heteroaryl, haloalkyl, or hydroxyalkyl, each occurrence of R9 is independently H, alkyl, alkenyl, alkynyl, - [C (R12) 2] q-aryl, - [C (R12) 2] q-cycloalkyl, - [C (R12) 2] q-cycloalkenyl, - [C (R12) 2] q-heterocycloalkyl, - [C (R12) 2] q-heterocycloalkenyl, - [C (R12) 2] q- heteroaryl, haloalkyl or hydroxyalkyl; R 10 is H, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, wherein a cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl or heteroaryl group may be optionally and independently substituted with up to 4 substituents, which are each selected from independently of H, alkyl, alkenyl, alkynyl, aryl, - [C (R12) 2] q-cycloalkyl, - [C (R12) 2] q-cycloalkenyl, - [C (R12) 2] q-heterocycloalkyl, - [C (R12) 2] q-heterocycloalkenyl, - [C (R12) 2] q-heteroaryl, - [C (R12) 2] q-haloalkyl, - [C (R12) 2] q-hydroxyalkyl, halo, hydroxy , -OR9, -CN, - [C (R12) 2] qC (O) R8, - [C (R12) 2] qC (O) OR9, - [C (R12) 2] qC (O) N (R9 ) 2, - [C (R12) 2] q-OR9, - [C (R12) 2] qN (R9) 2, - [C (R12) 2] q-NHC (O) R8, - [C (R12 ) 2] q-NR8C (O) N (R9) 2, - [C (R12) 2] q-NHSO2R11, - [C (R12) 2] qS (O) pR11, - [C (R12) 2] q -SO2N (R9) 2 and -SO2N (R9) C (O) N (R9) 2; such that when R1 is a bond, R10 is different from H; Each occurrence of R 11 is independently alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, haloalkyl, hydroxy, or hydroxyalkyl, wherein a cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl group may be optionally substituted or heteroaryl. and independently with up to 4 substituents, which are each independently selected from -H, alkyl, alkenium, alkynyl, aryl, - [C (R12) 2] q-cycloalkyl, - [C (R12) 2] q-cycloalkenyl , - [C (R12) 2] q-heterocycloalkyl, - [C (R12) 2] q-heterocycloalkenyl, - [C (R12) 2] q-heteroaryl, - [C (R12) 2] q-haloalkyl, - [C (R12) 2] q-hydroxyalkyl, halo, hydroxy, -OR9, -CN, - [C (R12) 2] qC (O) R8, - [C (R12) 2] qC (O) OR9, - [C (R12) 2] qC (O) N (R9) 2, - [C (R12) 2] q-OR9, - [C (R12) 2] qN (R9) 2, - [C (R12) 2 ] q-NHC (O) R8, - [C (R12) 2] q-NR8C (O) N (R9) 2, - [C (R12) 2] q-NHSO2alkyl, - [C (R12) 2] q -NHSO2cycloalkyl, - [C (R12) 2] q-NHSO2aryl, - [C (R12) 2] q-SO2N (R9) 2 and -SO2N (R9) C (O) N (R9) 2; each occurrence of R12 is independently H, halo, -N (R9) 2, -OR9, alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, wherein a cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl group may be optionally substituted and independently with up to 4 substituents, which are each independently selected from alkyl, halo, haloalkyl, hydroxyalkyl, hydroxy, -CN, -C (O) alkyl, -C (O) Oalkyl, -C (O) NH-alkyl , -C (O) N (alkyl) 2, -O-alkyl, -NH2, -NH (alkyl), -N (alkyl) 2, -NHC (O) alkyl, -NHSO2alkyl, -SO2alkyl or -SO2NH-alkyl , or two R12 geminal groups, together with the common carbon atom to which they are attached, join to form a 3- to 7-membered cycloalkyl group, 3 to 7-membered heterocycloalkyl or C = O; each occurrence of R30 is independently H, alkyl, alkenyl, alkynyl, aryl, - [C (R12) 2] qC (O) R8, - [C (R12) 2] qC (O) OR9, - [C ( R12) 2] qC (O) N (R9) 2, - [C (R12) 2] q-OR9, - [C (R12) 2] qN (R9) 2, - [C (R12) 2] q- NHC (O) R8, - [C (R12) 2] q-NR8C (O) N (R9) 2, - [C (R12) 2] q-NHSO2R11, - [C (R12) 2] qS (O) pR11, - [C (R12) 2] q-SO2N (R9) 2 and -SO2N (R9) C (O) N (R9) 2, or any R30 and R31, together with the carbon atoms to which they are linked , join to form a 3- to 7-membered cyclic group, selected from cycloalkyl, heterocycloalkyl, aryl and heteroaryl; R31 is H, alkyl, alkenyl, alkynyl, aryl; - [C (R12) 2] q-cycloalkyl, - [C (R12) 2] q-cycloalkenyl, - [C (R12) 2] q-heterocycloalkyl, - [C (R12) 2] q-heterocycloalkenyl, - [ C (R12) 2] q-heteroaryl, - [C (R12) 2] q-haloalkyl, - [C (R12) 2] q-hydroxyalkyl, halo, hydroxy, -OR9, -CN, each occurrence of p is of independent way 0, 1 or 2; each occurrence of q is independently an integer that varies from 0 to 4; and each occurrence of r is independently an integer that varies from 1 to 4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96868407P | 2007-08-29 | 2007-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR068109A1 true AR068109A1 (en) | 2009-11-04 |
Family
ID=40319417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103718A AR068109A1 (en) | 2007-08-29 | 2008-08-27 | TETRACICLIC DERIVATIVES OF INDOL AND A PHARMACEUTICAL COMPOSITION |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2197884A2 (en) |
JP (1) | JP5179585B2 (en) |
KR (1) | KR20100061819A (en) |
CN (1) | CN101842376A (en) |
AR (1) | AR068109A1 (en) |
AU (1) | AU2008295483B2 (en) |
CA (1) | CA2697451A1 (en) |
MX (1) | MX2010002316A (en) |
TW (1) | TW200918536A (en) |
WO (1) | WO2009032123A2 (en) |
ZA (1) | ZA201001391B (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5501251B2 (en) | 2008-01-11 | 2014-05-21 | アルバニー モレキュラー リサーチ, インコーポレイテッド | (1-Azinone) substituted pyridoindoles as MCH antagonists |
MX2010013630A (en) * | 2008-06-13 | 2010-12-21 | Schering Corp | Tricyclic indole derivatives and methods of use thereof. |
AU2009273327A1 (en) | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
JP2012503620A (en) | 2008-09-26 | 2012-02-09 | エフ.ホフマン−ラ ロシュ アーゲー | Pyrin or pyrazine derivatives for treating HCV |
KR20120011880A (en) | 2009-04-25 | 2012-02-08 | 에프. 호프만-라 로슈 아게 | Heterocyclic antiviral compounds |
JP2012528195A (en) | 2009-05-29 | 2012-11-12 | メルク・シャープ・アンド・ドーム・コーポレーション | Antibacterial compounds composed of three linked aryl moieties for treating diseases such as hepatitis C |
TWI428332B (en) | 2009-06-09 | 2014-03-01 | Hoffmann La Roche | Heterocyclic antiviral compounds |
BRPI1011744A2 (en) | 2009-06-24 | 2016-03-22 | Hoffmann La Roche | heterocyclic antiviral compound. |
US8618299B2 (en) | 2009-07-01 | 2013-12-31 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof |
US8637501B2 (en) | 2009-07-01 | 2014-01-28 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof |
US9073925B2 (en) | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
US8629158B2 (en) | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
MX2012003170A (en) | 2009-09-21 | 2012-04-11 | Hoffmann La Roche | Heterocyclic antiviral compounds. |
AU2010324871A1 (en) | 2009-11-25 | 2012-06-14 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
MX2012010392A (en) | 2010-03-09 | 2012-10-03 | Merck Sharp & Dohme | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases. |
KR101899604B1 (en) | 2010-05-02 | 2018-09-17 | 엑스제트 엘티디. | Printing system with self-purge, sediment prevention and fumes removal arrangements |
WO2012018534A2 (en) | 2010-07-26 | 2012-02-09 | Schering Corporation | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
WO2012041227A1 (en) * | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds for treating hepatitis c viral infection |
WO2012050848A1 (en) | 2010-09-29 | 2012-04-19 | Schering Corporation | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
WO2012088124A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof |
EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2012142085A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
US20140378416A1 (en) | 2011-09-14 | 2014-12-25 | Michael P. Dwyer | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
EP2909210A4 (en) | 2012-10-17 | 2016-04-06 | Merck Sharp & Dohme | 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
AR092959A1 (en) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | DERIVATIVES OF NUCLEOSIDS 2-METHYL SUBSTITUTED AND METHODS OF USE OF THE SAME FOR THE TREATMENT OF VIRAL DISEASES |
US9242988B2 (en) | 2012-10-17 | 2016-01-26 | Merck Sharp & Dohme Corp. | 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
AU2013344757A1 (en) | 2012-11-19 | 2015-05-21 | Merck Sharp & Dohme Corp. | 2 -alkynyl substituted nucleoside derivatives for treating viral diseases |
EP3010512B1 (en) | 2013-06-18 | 2017-12-27 | Merck Sharp & Dohme Corp. | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2014205593A1 (en) | 2013-06-24 | 2014-12-31 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases |
WO2014205592A1 (en) | 2013-06-24 | 2014-12-31 | Merck Sharp & Dohme Corp. | Heterocyclic compounds and methods of use thereof for treatment of hepatitis c |
EP3063140A4 (en) | 2013-10-30 | 2017-11-08 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
US10899788B2 (en) | 2016-06-20 | 2021-01-26 | Merck Sharp & Dohme Corp. | Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases |
CN112898312B (en) * | 2021-01-29 | 2021-11-12 | 湖南南新制药股份有限公司 | Fused polycyclic pyridone derivative and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
JP2008514611A (en) * | 2004-09-23 | 2008-05-08 | ワイス | Derivatives of carbazole and cyclopentaindole for treating infection with hepatitis C virus |
GB0518390D0 (en) * | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EP1940850A2 (en) * | 2005-09-23 | 2008-07-09 | Schering Corporation | Fused tetracyclic mglur1 antagonists as therapeutic agents |
-
2008
- 2008-08-27 EP EP08795628A patent/EP2197884A2/en not_active Withdrawn
- 2008-08-27 KR KR1020107006704A patent/KR20100061819A/en not_active Application Discontinuation
- 2008-08-27 TW TW097132762A patent/TW200918536A/en unknown
- 2008-08-27 AR ARP080103718A patent/AR068109A1/en not_active Application Discontinuation
- 2008-08-27 CN CN200880113543A patent/CN101842376A/en active Pending
- 2008-08-27 JP JP2010522933A patent/JP5179585B2/en not_active Expired - Fee Related
- 2008-08-27 AU AU2008295483A patent/AU2008295483B2/en not_active Ceased
- 2008-08-27 CA CA2697451A patent/CA2697451A1/en not_active Abandoned
- 2008-08-27 MX MX2010002316A patent/MX2010002316A/en not_active Application Discontinuation
- 2008-08-27 WO PCT/US2008/010147 patent/WO2009032123A2/en active Application Filing
-
2010
- 2010-02-25 ZA ZA2010/01391A patent/ZA201001391B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2010002316A (en) | 2010-03-22 |
CA2697451A1 (en) | 2009-03-12 |
JP5179585B2 (en) | 2013-04-10 |
AU2008295483B2 (en) | 2013-11-21 |
JP2010537980A (en) | 2010-12-09 |
KR20100061819A (en) | 2010-06-09 |
TW200918536A (en) | 2009-05-01 |
WO2009032123A3 (en) | 2009-06-11 |
WO2009032123A2 (en) | 2009-03-12 |
EP2197884A2 (en) | 2010-06-23 |
CN101842376A (en) | 2010-09-22 |
ZA201001391B (en) | 2010-11-24 |
AU2008295483A1 (en) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR068109A1 (en) | TETRACICLIC DERIVATIVES OF INDOL AND A PHARMACEUTICAL COMPOSITION | |
AR068108A1 (en) | AZAINDOL DERIVATIVES 2,3-SUBSTITUTES AND A PHARMACEUTICAL COMPOSITION | |
AR068107A1 (en) | INDOLIC DERIVATIVES 2.3 REPLACED AND A PHARMACEUTICAL COMPOSITION | |
AR068106A1 (en) | DERIVATIVES OF INDOL 2-CARBOXI SUBSTITUTED AND A PHARMACEUTICAL COMPOSITION | |
AR064428A1 (en) | INDOLIC DERIVATIVES WITH UNITED RING IN POSITIONS 4,5 AND THEIR METHODS OF USE. PHARMACEUTICAL COMPOSITIONS | |
AR064429A1 (en) | INDOLIC DERIVATIVES WITH UNITED RING IN POSITIONS 4,5, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USES OF THE SAME IN THE PREVENTION AND / OR TREATMENT OF VIRAL INFECTIONS. | |
AR064430A1 (en) | INDOLIC DERIVATIVES WITH UNITED RING IN THE POSITIONS 5.6. PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME. | |
AR082763A1 (en) | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT | |
AR051469A1 (en) | TETRACICLIC INDOL DERIVATIVES AS ANTIVIRICAL AGENTS | |
AR063545A1 (en) | DERIVATIVES OF TIAZOLS -1,3 AMINOSUSTITUIDOS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES AS ANTICANCER AGENTS | |
AR066459A1 (en) | DERIVATIVES OF OXADIAZOL AS MODULATORS OF GAMMA-SECRETASA. PHARMACEUTICAL COMPOSITIONS | |
PE20160501A1 (en) | USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS | |
ES2640911T3 (en) | Cycloalkyl nitrilpyrazolcarboxamides as Janus kinase inhibitors | |
AR084976A1 (en) | SUBSTITUTED BIFENYLENE COMPOUNDS AND METHODS OF USE OF THE SAME FOR THE TREATMENT OF VIRAL DISEASES | |
AR076024A1 (en) | DERIVATIVES OF BRIDGED BICYCLIC HETEROCICLES AND METHODS OF USE OF THE SAME | |
AR063219A1 (en) | DERIVATIVES OF AZETIDINONE, A COMPOSITION THAT UNDERSTANDS AND ITS USE IN THE TREATMENT OF PAIN AND DISORDERS OF LIPID METABOLISM. | |
AR061629A1 (en) | QUINOXALINIL MACROCICLIC INHIBITORS OF SERINE PROTEASE OF HEPATITIS VIRUS C. PROCESS OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS | |
SI2997033T1 (en) | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors | |
CO6251243A2 (en) | NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | |
AR048537A1 (en) | NUCLEOSID DERIVATIVES TO TREAT INFECTIONS BY HEPATITIS C VIRUSES. | |
RU2012117829A (en) | NOSLEOSIDE PHOSPHORAMIDATE DERIVATIVES | |
AR062050A1 (en) | USEFUL DERIVATIVES OF AMINA AS ANTI-CANCERIGEN AGENTS | |
AR072816A1 (en) | HETEROCICLIC DERIVATIVES OF PIRIDAZINA, SMO INHIBITORS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM AND USE OF THE SAME AS ANTICANCER AGENTS. | |
AR087182A1 (en) | INDOL DERIVATIVES SUBSTITUTED AS MODULATORS OF g SECRETASA | |
AR062666A1 (en) | BENZOTRIAZOLS AS KINASE MODULATORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |